AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.
Kristensson C, Åstrand A, Donaldson S, Goldwater R, Abdulai R, Patel N, Gardiner P, Tehler U, Mercier AK, Olsson M, Ersdal E, Mäenpää J, Bramer T, Malmgren A, Bennett W, Keen C.
Kristensson C, et al.
J Cyst Fibros. 2022 Jul;21(4):684-690. doi: 10.1016/j.jcf.2022.02.010. Epub 2022 Feb 26.
J Cyst Fibros. 2022.
PMID: 35227647
Free article.
Clinical Trial.
METHODS: A Phase I, first-in-human, single-blind, placebo-controlled, single ascending dose, sequential dose group study assessed the safety, tolerability, and pharmacokinetics of AZD5634 in healthy subjects (n=53) in part A following inhaled doses up to 1700 g, and, in pa …
METHODS: A Phase I, first-in-human, single-blind, placebo-controlled, single ascending dose, sequential dose group study assessed the safety …